- Home
- GIGM vs TLPH Comparison
GIGM vs TLPH Comparison
Compare GIGM & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | TLPH |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 64.7M |
| IPO Year | 2000 | 2011 |
Fundamental Metrics
Financial Performance| Metric | GIGM | TLPH |
|---|---|---|
| Price | $1.53 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 4.0K | ★ 430.0K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,397,000.00 | $28,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,267.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $0.38 |
| 52 Week High | $1.89 | $1.57 |
Technical Indicators
Market Signals| Indicator | GIGM | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 39.09 |
| Support Level | $1.50 | $1.20 |
| Resistance Level | $1.56 | $1.25 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 36.89 | 20.31 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.